HBM Pharma/Biotech M&A Report covering biopharma trade sales in the US and Europe from 2005 to 2014.
Key findings for 2014:
• $219.4 billion wordwide biopharma M&A transaction volume (including completed and announced deals, asset deals, acquisitions of divisions)
• $81.8 billion upfront transaction volume of completed US and European biopharma company trade sales (up from $48.5 billion in 2013). $87.7 billion overall deal value including contingent payments
• Additional $78.8 billion value of announced US & European transactions (including the $66 billion acquisition of Allergan by Actavis and the $8.4 billion purchase of Cubist by Merck & Co.)
• Further $45.6 billion worth of transactions involving assets or divisions of US and European companies.
• $13.3 billion deal volume of biopharma acquisitions outside of the US and Europe (ROW)
• Mid-sized pharma companies spent substantially more on acquisitions than traditional large pharma firms
• Best-ever exit year over last decade for VC-backed US biopharma companies
• 9 private-equity-backed pharma companies sold for over $10 billion
A list of transactions 2005-2014 can be found under www.hbmpartners.com/report.